Medy-Tox Inc.

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 60.5 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

Upper percentile

Top 15.8% in sector — Dividend yieldShareholder Return →Top 24.8% in sector — Operating marginFinancial strength →Top 26.9% in sector — Debt-to-equity ratioFinancial strength →

Lower percentile

Bottom 25.5% in sector — Operating income change (3Y)Growth momentum →

1-year closing price

Low ₩66,900High ₩138,600

Latest close

Price change by period

7.60%

1.30%

23.00%

38.60%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

Financial strength

64.6/100

How much debt does it carry relative to equity?

28.1%

Sector median 51.6%

Sector low

highTop 26.9% in sector

Can it cover what's due within a year?

148.2%

Sector median 191.7%

Sector low

highBottom 41.9% in sector

How much of revenue becomes profit?

6.9%

Sector median -2.4%

Sector low

highTop 24.8% in sector

How much did it earn on its own capital?

3.7%

Sector median -4.5%

Sector low

highTop 31.8% in sector

Source filing: annual report (consolidated) — view original ↗

Growth momentum

44.1/100

How much did revenue grow in a year?

8.2%

Sector median 6.4%

Sector low

highTop 43.4% in sector

Has it grown steadily over three years?

8.2%

Sector median 4.9%

Sector low

highTop 37.6% in sector

Did core profits grow in a year?

-16.4%

Sector median 3.6%

Sector low

highBottom 31.8% in sector

Are core profits higher than three years ago?

-63.6%

Sector median 3.5%

Sector low

highBottom 25.5% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

64.0/100

Is the price expensive relative to earnings?

32.1x

Sector median P/E of profitable peers 16.3x · 58% loss-making

Sector low

highTop 30.2% in sector

Is the price expensive relative to book value?

1.18x

Sector median 1.61x

Sector low

highTop 41.9% in sector

Valuation uses the Sep 1, 2026 close and market cap

Shareholder Return

Single-indicator axis84.2/100

Does the company actually pay dividends?

1.0%

Sector median 0.0%

Sector low

highTop 15.8% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025): ₩8.9B
Cash payout ratio, consolidated (FY2025): 53.8%
Treasury shares (FY2023): 568,242 shares (7.7% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 5 met · 3 not met · 1 not computable

Not metMetNot computable

Positive net income

Whether net income (attributable to owners where available) is above zero.

Met

₩16.6B

Positive operating cash flow

Whether cash flow from operations is above zero.

Met

₩61.4B

Return on assets up

Whether net income over beginning total assets rose from the prior year.

Not met

2.8% → 2.7%

Operating cash flow exceeds net income

Whether operating cash flow is greater than net income.

Met

₩61.4B vs ₩16.6B

Liabilities-to-assets ratio down

Whether total liabilities as a share of total assets fell from the prior year.

Met

23.5% → 21.9%

Current ratio up

Whether current assets over current liabilities rose from the prior year.

Not met

158.7% → 148.2%

Shares outstanding not increased

Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.

Not computable

Not computed — share count data is unavailable

Operating margin up

Whether operating income over revenue rose from the prior year.

Not met

8.9% → 6.9%

Asset turnover up

Whether revenue over beginning total assets rose from the prior year.

Met

0.37x → 0.40x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Corporate value-up plan filed

Filed a “기업가치제고계획(자율공시)” (corporate value-up plan, voluntary disclosure) (filed 2026-04-20). View filing ↗

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only

Periodic report filedAug 13, 2026Source ↗

Treasury stock acquisitionJun 9, 2026Source ↗

Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →